Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "Eli-Lilly"

93 News Found

Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
News | May 13, 2021

Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India

The agreement will help ensure wider reach and access to patients in India

Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
News | May 10, 2021

Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)

Lupin enters into agreement with Lilly to expand access for COVID-19
News | May 10, 2021

Lupin enters into agreement with Lilly to expand access for COVID-19

Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.

Latest Stories

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Granules India’s facility secures FDA EIR with 'VAI’

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging